The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All

Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marcin Skoreński, Marcin Sieńczyk
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	privileged structures enzyme inhibitors antivirals Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/2b657a5b81ef48aa9939e53c34d8aba8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2b657a5b81ef48aa9939e53c34d8aba8
record_format	dspace
spelling	oai:doaj.org-article:2b657a5b81ef48aa9939e53c34d8aba82021-11-25T18:39:51ZThe Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All10.3390/ph141111641424-8247https://doaj.org/article/2b657a5b81ef48aa9939e53c34d8aba82021-11-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1164https://doaj.org/toc/1424-8247Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structures typically exhibit good drug-like properties, thus assuring more drug-like properties of modified compound. Our main objective is to discuss the privileged structures used for the development of antiviral agents.Marcin SkoreńskiMarcin SieńczykMDPI AGarticleprivileged structuresenzyme inhibitorsantiviralsMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1164, p 1164 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	privileged structures enzyme inhibitors antivirals Medicine R Pharmacy and materia medica RS1-441
spellingShingle	privileged structures enzyme inhibitors antivirals Medicine R Pharmacy and materia medica RS1-441 Marcin Skoreński Marcin Sieńczyk The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
description	Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structures typically exhibit good drug-like properties, thus assuring more drug-like properties of modified compound. Our main objective is to discuss the privileged structures used for the development of antiviral agents.
format	article
author	Marcin Skoreński Marcin Sieńczyk
author_facet	Marcin Skoreński Marcin Sieńczyk
author_sort	Marcin Skoreński
title	The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_short	The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_full	The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_fullStr	The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_full_unstemmed	The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
title_sort	fellowship of privileged scaffolds—one structure to inhibit them all
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/2b657a5b81ef48aa9939e53c34d8aba8
work_keys_str_mv	AT marcinskorenski thefellowshipofprivilegedscaffoldsonestructuretoinhibitthemall AT marcinsienczyk thefellowshipofprivilegedscaffoldsonestructuretoinhibitthemall AT marcinskorenski fellowshipofprivilegedscaffoldsonestructuretoinhibitthemall AT marcinsienczyk fellowshipofprivilegedscaffoldsonestructuretoinhibitthemall
_version_	1718410823533068288

The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All

Ejemplares similares